Purity | Size | Price | VIP Price | USA Stock *0-1 Day | Global Stock *5-7 Days | Quantity | |||||
{[ item.p_purity ]} | {[ item.pr_size ]} |
{[ getRatePrice(item.pr_usd, 1,1) ]} {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]} |
{[ getRatePrice(item.pr_usd, 1,1) ]} | Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_usd,1,item.mem_rate) ]} | {[ item.pr_usastock ]} | Inquiry - | {[ item.pr_chinastock ]} | Inquiry - |
* Storage: {[proInfo.prStorage]}
CAS No. : | 54568-12-6 | MDL No. : | MFCD09909808 |
Formula : | C6H9N3 | Boiling Point : | - |
Linear Structure Formula : | - | InChI Key : | SMPCNKPYFMZJMO-UHFFFAOYSA-N |
M.W : | 123.16 | Pubchem ID : | 643252 |
Synonyms : |
|
Num. heavy atoms : | 9 |
Num. arom. heavy atoms : | 6 |
Fraction Csp3 : | 0.33 |
Num. rotatable bonds : | 0 |
Num. H-bond acceptors : | 2.0 |
Num. H-bond donors : | 1.0 |
Molar Refractivity : | 36.37 |
TPSA : | 51.8 Ų |
GI absorption : | High |
BBB permeant : | Yes |
P-gp substrate : | No |
CYP1A2 inhibitor : | No |
CYP2C19 inhibitor : | No |
CYP2C9 inhibitor : | No |
CYP2D6 inhibitor : | No |
CYP3A4 inhibitor : | No |
Log Kp (skin permeation) : | -6.61 cm/s |
Log Po/w (iLOGP) : | 1.36 |
Log Po/w (XLOGP3) : | 0.62 |
Log Po/w (WLOGP) : | 0.68 |
Log Po/w (MLOGP) : | 0.06 |
Log Po/w (SILICOS-IT) : | 1.06 |
Consensus Log Po/w : | 0.76 |
Lipinski : | 0.0 |
Ghose : | None |
Veber : | 0.0 |
Egan : | 0.0 |
Muegge : | 1.0 |
Bioavailability Score : | 0.55 |
Log S (ESOL) : | -1.49 |
Solubility : | 4.01 mg/ml ; 0.0325 mol/l |
Class : | Very soluble |
Log S (Ali) : | -1.28 |
Solubility : | 6.43 mg/ml ; 0.0522 mol/l |
Class : | Very soluble |
Log S (SILICOS-IT) : | -2.02 |
Solubility : | 1.17 mg/ml ; 0.00951 mol/l |
Class : | Soluble |
PAINS : | 0.0 alert |
Brenk : | 0.0 alert |
Leadlikeness : | 1.0 |
Synthetic accessibility : | 1.49 |
Signal Word: | Warning | Class: | N/A |
Precautionary Statements: | P261-P305+P351+P338 | UN#: | N/A |
Hazard Statements: | H302-H315-H319-H335 | Packing Group: | N/A |
GHS Pictogram: |
* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
42% | Stage #1: With Benzophenone imine; 2,2'-bis-(diphenylphosphino)-1,1'-binaphthyl; sodium t-butanolate In toluene at 80℃; for 1 h; Stage #2: With hydrogenchloride In tetrahydrofuran; water at 20℃; for 3 h; |
To a solution of 4-chloro-5,6-dimethylpyrimidine D8 (0.18 g, 1.26 mmol) in dry toluene (4 ml) were added sodium t-butoxyde (0.17 g, 1.77 mmol), Pd2(dba)3 (0.12 g, 0.13 mmol), BINAP (0.24 g, 0.38 mmol) and benzophenone imine (0.25 ml, 1.51 mmol). The resulting mixture was degassed (3 x pump/N2) and then heated to 80 0C. After 1 h stirring, the mixture was cooled down to room temperature, diluted with Et2O (100 ml) and filtered through a celite pad. Volatiles were evaporated, the resulting oil was dissolved in THF (20 ml) and HCl (3 M aqueous solution, 0.63 ml, 1.89 mmol) was added. The mixture was stirred at room temperature for 3 h, concentrated under reduced pressure, neutralized with a saturated NaHCO3 aqueous solution and diluted with DCM (50 ml). The inorganic layer was back-extracted with DCM (2 x 50 ml). The collected organic layers were passed through a phase separator tube and evaporated. The orange solid residue was triturated several times with Et2O and dried to afford the title compound D9 (0.067 g, 0.54 mmol, 42percent yield). 1H NMR (400 MHz, CDCl3) δ(ppm): 8.38 (s, 1 H), 4.78 (bs, 1 H), 2.43 (s, 3 H), 2.08 (s, 3 H). |
[ 76574-44-2 ]
4-Amino-6-methylpyrimidine-5-carbonitrile
Similarity: 0.85
[ 76574-44-2 ]
4-Amino-6-methylpyrimidine-5-carbonitrile
Similarity: 0.85